Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04033081 · ClinicalTrials.gov registry record · Phase 4
Registry of Sarcoma Patients Treated With Permanently Implantable LDR CivaSheet®
A Phase 4 study of Sarcoma, sponsored by CivaTech Oncology.
- Active
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT04033081 is a Phase 4 study of Sarcoma that is active but no longer recruiting, run by CivaTech Oncology. The registered enrollment target is 100 participants, below the 920-participant average among 122 other Sarcoma trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04033081, a Phase 4 study of Sarcoma, is active but no longer recruiting, sponsored by CivaTech Oncology.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This patient study will determine the safety and toxicity of a permanently implantable brachytherapy source - CivaSheet® - which is designed to deliver a therapeutic dose of low dose rate (LDR) radiation with polymer encased Palladium-103. CivaSheet will be implanted in sarcoma patients with disease presenting in the retroperitoneum, abdomen, pelvis and trunk.
Conditions Studied
Interventions
- DEVICE CivaSheet
Study Locations (1)
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2020-04-30 |
| Est. Completion | 2030-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04033081
The ClinicalTrials.gov registry entry for NCT04033081 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 920-participant average among 122 other Sarcoma trials with a reported enrollment target (89% lower). The listed sponsor is CivaTech Oncology, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which CivaSheet is the first listed.
NCT04033081 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04033081 about?
NCT04033081 is a clinical study titled "Registry of Sarcoma Patients Treated With Permanently Implantable LDR CivaSheet®". This patient study will determine the safety and toxicity of a permanently implantable brachytherapy source - CivaSheet® - which is designed to deliver a therapeutic dose of low dose rate (LDR) radiation with polymer encased Palladium-103. CivaSheet will be implanted in sarcoma patients with disease...
What is the current status of trial NCT04033081?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2020-04-30. Estimated completion is 2030-04.
What conditions does trial NCT04033081 study?
This clinical trial studies the following conditions: Sarcoma.
What interventions are being tested in trial NCT04033081?
The interventions under investigation include: CivaSheet (DEVICE).
Who is sponsoring clinical trial NCT04033081?
This trial is sponsored by CivaTech Oncology, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04033081 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hyperbaric Oxygen Therapy for Soft Tissue Sarcoma Pilot Study
RECRUITING · Phase 4
-
WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)
RECRUITING · NA
-
LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy in Sarcoma Patients
RECRUITING
-
Palbociclib and Pembrolizumab in Sarcoma
RECRUITING · Phase 1
-
Abductor Reattachment Methods in Proximal Femur Replacements: What is the Best Method?
RECRUITING
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.